Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,800 | 2017-12-19 00:00:00 UTC | First Week of August 2018 Options Trading For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/first-week-august-2018-options-trading-abbvie-abbv-2017-12-19 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red: Considering the fact that the $100.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $97.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $100.00 strike price has a current bid of $6.20. Below is a chart showing ABBV... | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new August 2018 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $100.00 strike highlighted in red: Consid... |
25,801 | 2017-12-19 00:00:00 UTC | Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma | ABBV | https://www.nasdaq.com/articles/bristol-myers-yervoy-gets-positive-chmp-opinion-for-melanoma-2017-12-19 | null | null | Bristol-Myers Squibb CompanyBMY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Yervoy for pediatric patients of 12 years and older with unresectable or metastatic melanoma.
We note that the European Commission will take the CHMP ... | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company rec... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company rec... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company rec... |
25,802 | 2017-12-18 00:00:00 UTC | The 5 Best-Selling Drugs of 2017 | ABBV | https://www.nasdaq.com/articles/5-best-selling-drugs-2017-2017-12-18 | null | null | We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.
Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celge... | With Humira likely to keep its momentum going, fast-growing sales for cancer drug Imbruvica, and a deep pipeline, AbbVie should be able to generate solid growth in the coming years. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie, Celgene, and Pfizer. Payers and patients across the wo... | Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this ye... | Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE) . AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this ye... | AbbVie is on course to make well over $18 billion from the autoimmune-disease drug this year. Payers and patients across the world are on track to spend $48 billion this year on just five drugs sold by AbbVie (NYSE: ABBV) , Amgen (NASDAQ: AMGN) , Celgene (NASDAQ: CELG) , Roche (NASDAQOTH: RHHBY) , and Pfizer (NYSE: PFE... |
25,803 | 2017-12-18 00:00:00 UTC | Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018 | ABBV | https://www.nasdaq.com/articles/why-no-large-cap-biotech-franchise-safe-threats-2018-2017-12-18 | null | null | No franchise is safe in 2018 among large-cap biotechs, which are feeling pressure as the Food and Drug Administration speeds approvals for rival branded and generic medicines, analysts said Monday.
[ibd-display-video id=3031092 width=50 float=left autostart=true] The theme is a continuation from 2017, Leerink analyst G... | Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. AbbVie recently launched Mavyret to trea... | Porges expects 2018 sales outlooks from Celgene, Alexion, Vertex Pharmaceuticals (VRTX), Gilead, Amgen (AMGN) and AbbVie to miss analyst estimates. Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug ... | Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. AbbVie recently launched Mavyret to trea... | Celgene is feeling the pain in its inflammation unit amid mounting competition from Eli Lilly ( LLY ) and Novartis ( NVS ), as Gilead sees a rival for its hepatitis C drug sales in AbbVie ( ABBV ). He noted AbbVie's plans for hepatitis C products are likely to hurt Gilead stock. Porges expects 2018 sales outlooks from ... |
25,804 | 2017-12-17 00:00:00 UTC | 3 Top Dividend Aristocrats to Buy for 2018 | ABBV | https://www.nasdaq.com/articles/3-top-dividend-aristocrats-buy-2018-2017-12-17 | null | null | It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends for 25 or more years in a row. But some Dividend Aristocrats are better than others.
Several of the nearly 50 Dividend Arist... | I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie'... | Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's ... | Most Dividend Aristocrat lists include AbbVie, crediting the big pharma with Abbott's years of dividend increases before AbbVie's spinoff in 2013. I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's ... | AbbVie. I'd put Abbott Labs (NYSE: ABT) , AbbVie (NYSE: ABBV) , and General Dynamics (NYSE: GD) near the top of the list. AbbVie There's also a whole lot to like about Abbott Lab's "child" -- AbbVie. |
25,805 | 2017-12-15 00:00:00 UTC | Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA | ABBV | https://www.nasdaq.com/articles/bristol-myers-opdivo-yervoy-sbla-for-rcc-accepted-by-fda-2017-12-15 | null | null | Bristol-Myers Squibb CompanyBMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for priority review of Opdivo plus Yervoy (ipilimumab) for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).
We note that the FDA had granted Breakthrou... | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company rec... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report To read this article on Zacks.com click here. The company rec... | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics... |
25,806 | 2017-12-15 00:00:00 UTC | AbbVie a Top Socially Responsible Dividend Stock With 3.0% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-top-socially-responsible-dividend-stock-30-yield-abbv-2017-12-15 | null | null | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis o... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis o... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis o... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis o... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 3.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis o... |
25,807 | 2017-12-15 00:00:00 UTC | Galapagos Cozies Up Closer to Gilead Sciences | ABBV | https://www.nasdaq.com/articles/galapagos-cozies-closer-gilead-sciences-2017-12-15 | null | null | Gilead Sciences (NASDAQ: GILD) inked a collaboration deal with Galapagos NV (NASDAQ: GLPG) in 2015 to gain rights to the latter's JAK1 inhibitor filgotinib. Today, Galapagos decided to execute its co-commercialization rights to filgotinib in several European countries. The move comes only weeks ahead of a standstill ag... | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year ... | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year ... | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year ... | Gilead Sciences swooped in with enough money to license it and acquire a nearly 13.3% equity ownership stake in Galapagos after AbbVie Inc. (NYSE: ABBV) walked away from its license to focus on its own autoimmune disease drugs. That's because biologics used in autoimmune diseases, such as AbbVie's $18 billion per year ... |
25,808 | 2017-12-15 00:00:00 UTC | Noteworthy ETF Inflows: VYM, ABBV, GILD, LLY | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vym-abbv-gild-lly-2017-12-15 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $209.2 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 246,531... | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year ... | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year ... | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of VYM, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.9%, Gilead Sciences Inc (Symbol: GILD) is up about 1.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
25,809 | 2017-12-15 00:00:00 UTC | Stocks With Rising Relative Price Strength: Horizon Pharma | ABBV | https://www.nasdaq.com/articles/stocks-rising-relative-price-strength-horizon-pharma-2017-12-15 | null | null | Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday.
[ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 we... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday. Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating in the ea... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Sho... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action... |
25,810 | 2017-12-15 00:00:00 UTC | Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion | ABBV | https://www.nasdaq.com/articles/pfizers-arthritis-drug-gets-fda-nod-for-label-expansion-2017-12-15 | null | null | Pfizer Inc.PFE announced that the FDA has approved a label expansion for its janus kinase (JAK) inhibitor, Xeljanz (tofacitinib), for two doses - 5 mg twice daily and 11 mg once-daily extended-release (XR) formulation.
With this latest approval, Xeljanz can now be administered for treating adult patients with active ps... | Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, Pfizer is conducting a phase IIIb/IV h... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, Pfizer is conducting a phase IIIb/IV h... | Additionally, Pfizer is conducting a phase IIIb/IV head-to-head study comparing Xeljanz with AbbVie's ABBV Humira. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock... |
25,811 | 2017-12-15 00:00:00 UTC | What to Expect From AbbVie Inc. in 2018 | ABBV | https://www.nasdaq.com/articles/what-expect-abbvie-inc-2018-2017-12-15 | null | null | In the words of the legendary James Brown, I feel good.
Early this year, I bought a position in AbbVie (NYSE: ABBV) . The big pharma stock is on track for 2017 to be its best year ever . And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the sto... | AbbVie and J&J should announce results from a late-stage study of Imbruvica in combination with other drugs in treating diffuse large B-cell lymphoma (DLBCL) in mid-2018 as well. Early this year, I bought a position in AbbVie (NYSE: ABBV) . And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-da... | AbbVie expects that the drug will generate sales topping $18 billion this year. This total doesn't reflect revenue that Imbruvica generates for AbbVie's partner, Johnson & Johnson (NYSE: JNJ) . Early this year, I bought a position in AbbVie (NYSE: ABBV) . | Another great year for Humira and Imbruvica As Humira goes, so goes AbbVie. AbbVie expects that the drug will generate sales topping $18 billion this year. I expect 2018 sales for the drug will increase by 30% to 35%, which would add at least $750 million to AbbVie's top line next year. | I think that the FDA will approve the drug for treating endometriosis, and I expect another successful launch for AbbVie. Early this year, I bought a position in AbbVie (NYSE: ABBV) . And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock. |
25,812 | 2017-12-14 00:00:00 UTC | Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors | ABBV | https://www.nasdaq.com/articles/stock-market-overpriced-yes-not-these-3-sectors-2017-12-14 | null | null | Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more than 63% higher than its historical average value.
The problem with using valuation metrics that look in the rearview mirror, tho... | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of A... | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of A... | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of A... | AbbVie (NYSE: ABBV) , on the other hand, has had a terrific year that only picked up steam over the last few months. With continued momentum for top-selling Humira and a strong pipeline, AbbVie definitely looks like a healthcare stock to buy. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of A... |
25,813 | 2017-12-14 00:00:00 UTC | Pfizer's Second Biosimilar of Remicade Receives FDA Approval | ABBV | https://www.nasdaq.com/articles/pfizers-second-biosimilar-of-remicade-receives-fda-approval-2017-12-14 | null | null | Pfizer Inc.PFE announced that the FDA has approved Ixifi its second biosimilar version of Johnson & Johnson's JNJ blockbuster rheumatoid arthritis ("RA") drug, Remicade (infliximab). Notably, Ixifi is a chimeric human-murine monoclonal antibody against tumor necrosis factor.
Ixifi received the nod for all approved indi... | Biosimilar products in late-stage development include biosimilar versions of Roche's RHHBY Rituxan and Avastin and AbbVie's ABBV Humira. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report A... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilar products in late-stage development... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilar products in late-stage development... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilar products in late-stage development... |
25,814 | 2017-12-14 00:00:00 UTC | Horizon Pharma Earns RS Rating Upgrade | ABBV | https://www.nasdaq.com/articles/horizon-pharma-earns-rs-rating-upgrade-2017-12-14 | null | null | Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock'... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77. Try This Simple Routine Now is not an ideal time to jump in since it i... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Horizon Pharma ( HZNP ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, with an increase from 64 to 77. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising ... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Over 100 years of market history reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. Biotech And Pharmaceutical Industry And Stock News Stocks... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database. Over 100 years of market history reveals that the market's biggest winners often ... |
25,815 | 2017-12-13 00:00:00 UTC | 6 Dividend Growth Stocks to Stay Ahead of Rising Interest Rates | ABBV | https://www.nasdaq.com/articles/6-dividend-growth-stocks-stay-ahead-rising-interest-rates-2017-12-13 | null | null | For years, America's low-interest-rate environment has pushed income hunters out of bonds and into other cash-producing investments - namely, dividend stocks . However, the Federal Reserve has been slowly turning the volume back up on interest rates, and is poised to do so again Wednesday, Dec. 13, at the conclusion of... | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darli... | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darli... | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darli... | SEE ALSO: 50 Dividend Stocks You Can Count On in 2018 Dividend Yield: 3.0% AbbVie ( ABBV , $96.31) is a global biopharmaceutical company that targets autoimmune diseases, oncology, and viral and neurological disorders. Since its spinoff from Abbott Laboratories ( ABT ) in January 2013, ABBV has been a Wall Street darli... |
25,816 | 2017-12-12 00:00:00 UTC | AbbVie Makes Progress on Quest to Diversify | ABBV | https://www.nasdaq.com/articles/abbvie-makes-progress-quest-diversify-2017-12-12 | null | null | AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. Fortunately, there's still time to develop blockbuster drugs that can help offset any eventual slowing in Humira demand.
Today, AbbVie... | AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide sales. Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expa... | Two titans team up AbbVie's global Humira sales are clocking in at an annualized $18 billion annually, and that makes expanding the addressable market for drugs like Venclexta important. AbbVie' s (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira gener... | Today, AbbVie and collaboration partner Roche Holdings (NASDAQOTH: RHHBY) reported new data on Venclexta that could significantly expand its use and drive its revenue higher, helping AbbVie make up for any drop in future sales. Two titans team up AbbVie's global Humira sales are clocking in at an annualized $18 billion... | Nevertheless, a multibillion dollar forecast doesn't seem too off base when you consider that Imbruvica, a J&J and AbbVie drug, is a multibillion-dollar drug and it generates most of its sales from treating CLL. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and... |
25,817 | 2017-12-12 00:00:00 UTC | Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-reports-positive-data-on-leukemia-drug-2017-12-12 | null | null | Bristol-Myers Squibb CompanyBMY announced positive data from phase II study, CA180-372, on Sprycel.
Patients received Sprycel 60 mg/m2tablets or powder for oral suspension, once daily, in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years or until the occurrence o... | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharma... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The co... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The co... | The company recently entered into a deal with AbbVie, Inc. ABBV and Halozyme Therapeutics, Inc. HALO . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Sucampo Pharma... |
25,818 | 2017-12-12 00:00:00 UTC | Novartis Announces Positive Data on Sickle Cell Disease Drug | ABBV | https://www.nasdaq.com/articles/novartis-announces-positive-data-on-sickle-cell-disease-drug-2017-12-12 | null | null | Novartis AGNVS announced positive results from a post hoc subgroup analysis of the phase II study, SUSTAIN on pipeline candidate, crizanlizumab.
The multicenter, multinational, randomized, placebo-controlled, double-blind, 12-month study was conducted to evaluate the safety and efficacy of the anti-P-selectin antibody ... | The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The biosimilar version of AbbVie,... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. The biosimilar version of AbbVie,... | The biosimilar version of AbbVie, Inc. ABBV 's Humira is also under review in the EU. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis ... |
25,819 | 2017-12-10 00:00:00 UTC | Is Gilead Sciences, Inc. a Buy? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc-buy-2017-12-10 | null | null | With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. After getting off to a rocky start, the biotech's share price gained significant momentum beginning in June thanks to better-than-expected second-quarte... | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. After getting off to a rocky start, the biotech's share price gained significant momentum beginning in June thanks to bet... | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish rou... | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. Why buy Gilead? | It's shaping up to be pretty much a one-on-one battle between Gilead and AbbVie in the market. *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Gilead Sciences. But most investors aren't limited to just buying one stock. |
25,820 | 2017-12-10 00:00:00 UTC | Better Buy: Pfizer (PFE) vs. AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/better-buy-pfizer-pfe-vs-abbvie-abbv-2017-12-10 | null | null | For Pfizer (NYSE: PFE) , 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down about. AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. The stock is up more than 50% and is ... | *Stock Advisor returns as of December 4, 2017 Keith Speights owns shares of AbbVie and Pfizer. AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? | AbbVie, meanwhile, has relied on its powerhouse autoimmune disease drug Humira to drive growth in the past, and the company expects continued, albeit slowing sales growth for the drug. Two especially promising candidates for AbbVie are autoimmune disease drug upadacitinib and cancer drug Rova T. Wall Street analysts pr... | Two especially promising candidates for AbbVie are autoimmune disease drug upadacitinib and cancer drug Rova T. Wall Street analysts project that Pfizer will increase annual earnings by around 6% in the coming years, an improvement over the drugmaker's recent growth. AbbVie's trailing earnings multiple stands at 23, wi... | * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie 's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? |
25,821 | 2017-12-08 00:00:00 UTC | Noteworthy Friday Option Activity: UAL, GILD, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ual-gild-abbv-2017-12-08 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in United Continental Holdings Inc (Symbol: UAL), where a total of 16,533 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 44.2% of UAL's average daily tradin... | Especially high volume was seen for the $95 strike call option expiring February 16, 2018 , with 5,584 contracts trading so far today, representing approximately 558,400 underlying shares of ABBV. Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And Ab... | Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over t... | Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over t... | Below is a chart showing GILD's trailing twelve month trading history, with the $73.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,217 contracts, representing approximately 1.8 million underlying shares or approximately 40.1% of ABBV's average daily trading volume over t... |
25,822 | 2017-12-08 00:00:00 UTC | The No. 7 Drug Maker Is This Week's No. 1 Pick | ABBV | https://www.nasdaq.com/articles/no-7-drug-maker-weeks-no-1-pick-2017-12-08 | null | null | Note From The Editor:Today's issue is written by Amber Hestla, a former military intelligence operative. She's spent the last few years using an income-producing strategy she first began developing while serving in Iraq.
But before we get to today's issue, we want to take just a quick second to share something with you... | How You Can Win Almost Every Time What many investors don't know is that this expected price move also sets up a high-probability, high-income opportunity in AbbVie using short-term options. There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidati... | AbbVie is working to develop other drugs before sales of Humira start to decline (expected next year). There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV ) . ABBV sold off... | If ABBV is trading under the expected price when your options expire in 15 days, you get to essentially buy the stock at an even greater discount (a full 6.0% less), leaving you with a solid stock at a price you could never get by waiting for price drops. There are precise rules for this charting pattern, but the most ... | AbbVie is working to develop other drugs before sales of Humira start to decline (expected next year). How You Can Win Almost Every Time What many investors don't know is that this expected price move also sets up a high-probability, high-income opportunity in AbbVie using short-term options. There are precise rules fo... |
25,823 | 2017-12-06 00:00:00 UTC | AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan | ABBV | https://www.nasdaq.com/articles/abbvie-jjs-imbruvica-succeeds-in-combo-study-with-rituxan-2017-12-06 | null | null | AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint.
Interim data from the phase III iNNOVATE study ... | AbbVie and J&J plan to discuss the positive interim data with regulatory authorities Imbruvica is already approved as a monotherapy for the treatment of WM. AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruv... | In 2017, AbbVie expects to record Imbruvica global revenues of more than $2.4 billion with sales in the United States expected to cross $2 billion. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analys... | AbbVie Inc.ABBV and partner Janssen, Johnson & Johnson's JNJ pharmaceuticals subsidiary, announced that a combination study evaluating their key cancer drug Imbruvica in Waldenström's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, met the primary endpoint. In fact, AbbVie expects Imbruvica peak sales of... | AbbVie and J&J plan to discuss the positive interim data with regulatory authorities Imbruvica is already approved as a monotherapy for the treatment of WM. In fact, AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020 At present, the CLL segment is the largest revenue co... |
25,824 | 2017-12-06 00:00:00 UTC | Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-amgen-pcsk9-inhibitor-revance-rt002-data-2017-12-06 | null | null | This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates.
Recap of the Week's Most Important Stories
Revan... | AbbVie also presented data on a combination of its BTK inhibitor, Imbruvica, and Rituxan for the treatment of both newly and previously-treated patients with Waldenström's macroglobulinemia ("WM"). This week, companies like Amgen AMGN , Revance Therapeutics, Inc. RVNC and AbbVie ABBV were in the news. While Amgen got F... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Revance Therapeutics, Inc.... | While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Amgen Inc... | While Amgen got FDA approval for the inclusion of cardiovascular outcomes data for its PCSK9 inhibitor, AbbVie and Revance provided data on their pipeline candidates. Positive Data on AbbVie's Risankizumab and Imbruvica: AbbVie's risankizumab met the primary endpoint in the fourth pivotal phase III study conducted for ... |
25,825 | 2017-12-05 00:00:00 UTC | AbbVie Psoriasis Candidate Succeeds in 4th Phase III Study | ABBV | https://www.nasdaq.com/articles/abbvie-psoriasis-candidate-succeeds-in-4th-phase-iii-study-2017-12-05 | null | null | AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints.
Top line data from the IMMhance study showed that a significant portion of patients ... | AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. AbbVie had in-licensed risankizumab from Boehringer Ingelheim in 2016. AbbVie is res... | AbbVie, Inc.ABBV announced that a fourth pivotal phase III study evaluating its investigational IL-23 inhibitor, risankizumab for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. We remind investors that in October, AbbVie had announced that three pivotal head-to... | We remind investors that in October, AbbVie had announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and AbbVie's Humira, for the treatment of moderate-to-severe chronic plaque psoriasis, met all co-primary and secondary endpoints. Click to get this ... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that a fourth pivotal... |
25,826 | 2017-12-05 00:00:00 UTC | Valeant Pharmaceuticals Joins Elite Club Of Stocks With RS Ratings Over 90 | ABBV | https://www.nasdaq.com/articles/valeant-pharmaceuticals-joins-elite-club-stocks-rs-ratings-over-90-2017-12-05 | null | null | Valeant Pharmaceuticals ( VRX ) had its Relative Strength ( RS ) Rating upgraded from 88 to 91 Tuesday.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stoc... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. History reveals that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new climb. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Valeant Pharmaceuticals ( VRX ) had its Relative Strength ( RS ) Rating upgraded from 88 to 91 Tuesday. Biotech And Pharmaceutical Industry And Stock News Stocks With Rising Relative Strength Ratings Why Shoul... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the oth... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the oth... |
25,827 | 2017-12-04 00:00:00 UTC | Top Biotech Stock Near Buy Zone, Shows Positive Drug Trial Results | ABBV | https://www.nasdaq.com/articles/top-biotech-stock-near-buy-zone-shows-positive-drug-trial-results-2017-12-04 | null | null | On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. On Tuesday, the IBD Big Cap 20 was up fractionally and within 3% of a potential new buy zone.
[ibd-display-video id=2102289 width=50 float=left autostart=true] Results of the ongoing study sh... | Like AbbVie, Edwards Lifesciences is working on a new base, and managed health care provider Centene, which broke out last week, is again testing the 98.82 buy point. AbbVie blasted past a 75.14 buy point in early September, reaching a peak of 98.26 on Oct. 20 before pulling back to begin forming its current second-sta... | Dividend Stock With Growth For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters. On Monday, leading drugmaker AbbVie ( ABBV ) announced positive Phase 3 trial results for its psoriasis treatment, risankizumab. AbbVie, which generate... | Dividend Stock With Growth For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters. While forming that chart pattern, AbbVie sold off sharply on Oct. 26, but found support at the 50-day moving average and bounced back to close the day ... | Dividend Stock With Growth For a company of its size, AbbVie continues to generate solid growth, with revenue gains ranging from 8% to 18% over the last eight quarters. While AbbVie slipped over 1% Monday, volume was below average and the stock found support right around its 10-day line. On Monday, leading drugmaker Ab... |
25,828 | 2017-12-04 00:00:00 UTC | Lilly's (LLY) Taltz Gets Approval for Label Expansion in US | ABBV | https://www.nasdaq.com/articles/lillys-lly-taltz-gets-approval-for-label-expansion-in-us-2017-12-04 | null | null | Eli Lilly and CompanyLLY announced that the FDA has approved the label expansion of its psoriasis drug, Taltz, to include the treatment of active psoriatic arthritis (PsA) in adults.
We note that Taltz is presently approved for treating moderate-to-severe plaque psoriasis in adults who can have systemic therapy or phot... | Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie In... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Cosentyx, Johnson & Johnson's JN... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Cosentyx, Johnson & Johnson's JN... | Apart from Cosentyx, Johnson & Johnson's JNJ Stelara and AbbVie Inc.'s ABBV Humira among others are fighting for market share. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie In... |
25,829 | 2017-12-04 00:00:00 UTC | Does Steady Earnings Growth Lead To Big Dividends? | ABBV | https://www.nasdaq.com/articles/does-steady-earnings-growth-lead-big-dividends-2017-12-04 | null | null | You're looking for dividend stocks to invest in as a source of steady income, so how much emphasis should you put on fundamentals? A lot.
[ibd-display-video id=2531707 width=50 float=left autostart=true] That's because if you want steady income you want to own the best dividend stocks - companies that offer above-marke... | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). In addition to the daily column, you'll find three accompanying screens online and on The Income Investor page in the weekly edition. Though not immune to a slowing economy, t... | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). [ibd-display-video id=2531707 width=50 float=left autostart=true] That's because if you want steady income you want to own the best dividend stocks - companies that offer abov... | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). [ibd-display-video id=2531707 width=50 float=left autostart=true] That's because if you want steady income you want to own the best dividend stocks - companies that offer abov... | A few other standout names on the list in terms of YTD price gains are Cisco Systems ( CSCO ), Toronto Dominion Bank ( TD ) and AbbVie ( ABBV ). At the predividend cut annual payout of 96 cents a share, the stock's $13 decline this year offset the payouts earned over the past 13 years. In addition to the daily column, ... |
25,830 | 2017-12-01 00:00:00 UTC | 3 Drug/Biotech Stocks in Focus on World AIDS Day | ABBV | https://www.nasdaq.com/articles/3-drug-biotech-stocks-in-focus-on-world-aids-day-2017-12-01 | null | null | Every year, World Aids Day is celebrated on Dec 1 to raise public awareness about Acquired Immuno Deficiency Syndrome, popularly known as AIDS. The day is observed to make people aware about proper cure and prevention of the disease. In this regard, this year, the theme for the day this year is "Right to Health." This ... | Others Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Sto... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free... | Others Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Sto... |
25,831 | 2017-11-30 00:00:00 UTC | AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why | ABBV | https://www.nasdaq.com/articles/abbvie-stock-up-more-than-30-so-far-in-2h17%3A-heres-why-2017-11-30 | null | null | AbbVie Inc.ABBV shares have gained 32.1% so far in the second half of the year, comparing favorably with a gain of only 3.8 % recorded by the industry .
Resolution of Amgen Lawsuit
AbbVie announced the resolution of a patent dispute with Amgen Inc. AMGN in September, which has delayed the launch of the latter's biosimi... | This agreement has removed a major overhang on AbbVie's shares though the company is still facing a patent challenge from Boehringer Ingelheim, which gained approval for its biosimilar version of Humira, Cyltezo, in August. Moreover, the agreement gives AbbVie ample time to focus on developing its pipeline and launchin... | Positive Data from Studies AbbVie announced positive data from the phase III MURANO study of Venclexta plus plus Roche's RHHBY Rituxan in relapse/refractory CLL last month. In October, AbbVie announced that three pivotal head-to-head phase III studies evaluating risankizumab versus Johnson & Johnson's JNJ Stelara and H... | Resolution of Amgen Lawsuit AbbVie announced the resolution of a patent dispute with Amgen Inc. AMGN in September, which has delayed the launch of the latter's biosimilar version of AbbVie's blockbuster arthritis drug, Humira in the United States to 2023 and in most countries in the EU to October 2018. In October, AbbV... | In August, AbbVie gained approval for the sixth indication for Imbruvica. AbbVie's oral JAK-1 selective inhibitor, upadacitinib (ABT-494) met primary endpoints in a phase III study for the treatment of RA with highly statistically significant and clinically meaningful results for both the doses (15 mg and 30 mg) of upa... |
25,832 | 2017-11-30 00:00:00 UTC | The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon-abbvie-biogen-mccormick-and-hyatt-2017-11-30 | null | null | For Immediate Release
Chicago, IL - November 30, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , ... | Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , BiogenBIIB , McCormickMKC and HyattH . Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily featu... | Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. Click to get this free repor... | Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Biogen The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. Click to get this free repor... | Today's Research Daily features new research reports on 16 major stocks, including Amazon, AbbVie and Biogen. Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , BiogenBIIB , McCormickMKC and HyattH . Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, AbbVie and Bioge... |
25,833 | 2017-11-30 00:00:00 UTC | Notable Thursday Option Activity: MA, ABBV, ADP | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-ma-abbv-adp-2017-11-30 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mastercard Inc (Symbol: MA), where a total of 12,971 contracts have traded so far, representing approximately 1.3 million underlying shares. That amounts to about 41.3% of MA's average daily trading volume over ... | Particularly high volume was seen for the $105 strike call option expiring January 19, 2018 , with 11,749 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: Abb... | Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past ... | Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past ... | Below is a chart showing MA's trailing twelve month trading history, with the $144 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 18,841 contracts, representing approximately 1.9 million underlying shares or approximately 40.6% of ABBV's average daily trading volume over the past ... |
25,834 | 2017-11-30 00:00:00 UTC | Valeant Pharmaceuticals Shows Rising Price Performance With Jump To 83 RS Rating | ABBV | https://www.nasdaq.com/articles/valeant-pharmaceuticals-shows-rising-price-performance-jump-83-rs-rating-2017-11-30 | null | null | Valeant Pharmaceuticals ( VRX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 78 to 83.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's pri... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Valeant Pharmaceuticals ( VRX ) saw a positive improvement to its Relative Strength ( RS ) Rating on Thursday, rising from 78 to 83. See if the stock forms a new pattern or follow-on buying opportunity like a ... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Rising Relative Strength? Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over th... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. Try This Simple Routine Valeant Pharmaceuticals is now considered extended and out of buy range after clearing a 15.84 buy point in a first-stage cup with handle . Biotech And Pharmaceutical Industry And Stock... |
25,835 | 2017-11-29 00:00:00 UTC | iShares Russell Top 200 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-top-200-growth-etf-experiences-big-outflow-2017-11-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $83.5 million dollar outflow -- that's a 8.1% decrease week over week (from 14,200,000.00 to 13,050,00... | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year... | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year... | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ... | Among the largest underlying components of IWY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.1%, Priceline Group Inc (Symbol: PCLN) is down about 1.8%, and Lilly (Eli) & Co (Symbol: LLY) is lower by about 0.5%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year... |
25,836 | 2017-11-29 00:00:00 UTC | 3 Top Big Pharma Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2017-11-29 | null | null | Big pharma stocks have been longtime favorites among investors for several reasons. The fact that they're big means that that they generate huge cash flow, which typically translates to attractive dividends. And big pharma companies operate in a growing industry, with demand for prescription drugs continuing to rise --... | I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. AbbVie There's a lot for investors to like about AbbVie. Since being spun off from Abbott Labs in 2013, AbbVie has increased its dividend by a whopping 77.5%. | Johnson & Johnson Johnson & Johnson's dividend yield of 2.37% isn't as high as AbbVie's. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. AbbVie There's a lot for investors to like about AbbVie. | Johnson & Johnson Johnson & Johnson's dividend yield of 2.37% isn't as high as AbbVie's. Like AbbVie, Johnson & Johnson also has a pipeline ranked in the top five among all big pharma companies. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. | Like AbbVie, Johnson & Johnson also has a pipeline ranked in the top five among all big pharma companies. I think AbbVie is the best big pharma stock of all right now. I'd put AbbVie (NYSE: ABBV) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) at the top of the list. |
25,837 | 2017-11-29 00:00:00 UTC | 12 Best Dividend Stocks for the Next 12 Months | ABBV | https://www.nasdaq.com/articles/12-best-dividend-stocks-next-12-months-2017-11-29 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Finding the best dividend stocks involves looking beyond the next few weeks and thinking about a long-term investment. After all, if you're only in a dividend stock for a short time then you may not get the full yield that's based on a full year of payouts.... | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% fo... | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% fo... | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% fo... | The 10 Best Stocks for Your 401k This is a great cyclical dividend play for the next few years as a result of rising rents and property values in 2018. Dividend Stocks to Buy Now: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Sector: Healthcare Market Cap: $153 billion Yield: 3% YTD Return: 52% vs. 17% fo... |
25,838 | 2017-11-27 00:00:00 UTC | Valeant Pharmaceuticals Earns Technical Rating Upgrade | ABBV | https://www.nasdaq.com/articles/valeant-pharmaceuticals-earns-technical-rating-upgrade-2017-11-27 | null | null | On Monday, Valeant Pharmaceuticals ( VRX ) earned a positive adjustment to its Relative Strength ( RS ) Rating , from 66 to 71.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up a... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. On Monday, Valeant Pharmaceuticals ( VRX ) earned a positive adjustment to its Relative Strength ( RS ) Rating , from 66 to 71. History shows that the market's biggest winners tend to have an 80 or higher RS R... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of th... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. [ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of th... | AbbVie ( ABBV ), Zoetis ( ZTS ) and Grifols ( GRFS ) are among the top 5 highly rated stocks within the group. On Monday, Valeant Pharmaceuticals ( VRX ) earned a positive adjustment to its Relative Strength ( RS ) Rating , from 66 to 71. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Risin... |
25,839 | 2017-11-24 00:00:00 UTC | 3 Companies Competing to Gain Lead in Ovarian Cancer Market | ABBV | https://www.nasdaq.com/articles/3-companies-competing-to-gain-lead-in-ovarian-cancer-market-2017-11-24 | null | null | Until 2014, very few options were available to treat ovarian cancer and these primarily included chemotherapy, radiation or surgery. Though effective, these treatments had many side-effects. While chemotherapy can destroy a patient's immune system, radiation kills normal cells along with cancerous cells. A surgical pro... | There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & C... | There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & C... | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS... | There are many other companies developing PARP inhibitors including Pfizer Inc. PFE and AbbVie Inc. ABBV , among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Merck & C... |
25,840 | 2017-11-24 00:00:00 UTC | Will New Drug Approvals Boost Novartis (NVS) Portfolio? | ABBV | https://www.nasdaq.com/articles/will-new-drug-approvals-boost-novartis-nvs-portfolio-2017-11-24 | null | null | Novartis AGNVS is currently going through a transitional stage. The company's blockbuster drug, Diovan, is facing stiff generic competition in the United States, EU and Japan. The loss of patent protection for these top-selling drugs continues to hurt sales. Exforge is also facing generic competition in the United Stat... | The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis R... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake of Cosentyx has been strong and the compa... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The uptake of Cosentyx has been strong and the compa... | The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals AbbVie Inc.'s ABBV Humira and Amgen, Inc.'s AMGN Enbrel. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis R... |
25,841 | 2017-11-24 00:00:00 UTC | J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space | ABBV | https://www.nasdaq.com/articles/jj-glaxos-jucala-approval-puts-spotlight-on-hiv-space-2017-11-24 | null | null | Johnson & JohnsonJNJ and partner GlaxoSmithKline GSK recently announced FDA approval for Juluca - a combination of Glaxo's Tivicay/rilpivirine and J&J's Edurant/dolutegravir into a single tablet - for the treatment of HIV
Most medicines for HIV treatment are made up of three or more antiretroviral drugs. Juluca is the ... | The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Fr... | The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Fr... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Mylan N.V. (MYL): Free S... | The company's other marketed HIV drugs include Triumeq and Tivicay.Other popular marketed HIV drugs are AbbVie's ABBV Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Merck & Company, Inc. (MRK): Fr... |
25,842 | 2017-11-21 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-11-21 | null | null | They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each other in the autoimmune disease market.
Johnson & Johnson has been a longtime favorite among investors. AbbVie has arguably been ... | Although AbbVie is experiencing sales declines for some of its older hepatitis C and HIV drugs, those products combined make up for only a small percentage of total revenue. The impressive cash flow produced by Humira and (to a lesser extent) AbbVie's other drugs has allowed the company to reward shareholders with one ... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. Overall, Wall Street analysts project average annual earnings growth for AbbVie of nearly 16% over the next five years. AbbVie has arguably been the best big pharma stock in recent years. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. AbbVie has arguably been the best big pharma stock in recent years. Here's how AbbVie and J&J compare in the key categories of growth prospects, dividends, and valuation. | However, in my view, AbbVie is the better stock right now. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. AbbVie has arguably been the best big pharma stock in recent years. |
25,843 | 2017-11-20 00:00:00 UTC | Galapagos' CF Candidate Shows Potential in Phase II Study | ABBV | https://www.nasdaq.com/articles/galapagos-cf-candidate-shows-potential-in-phase-ii-study-2017-11-20 | null | null | Galapagos NVGLPG announced positive top-line data from a phase II study - ALBATROSS - evaluating its cystic fibrosis transmembrane conductance ("CFTR") corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function.
So far this year, Galapagos'shares have outperformed the ind... | All three candidates are being developed in partnership with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free S... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. All three can... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report To read this article on Zacks.com click here. All three can... | All three candidates are being developed in partnership with AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free S... |
25,844 | 2017-11-20 00:00:00 UTC | Galapagos Pops To Vertex's Detriment — But Can It Compete? | ABBV | https://www.nasdaq.com/articles/galapagos-pops-vertexs-detriment-can-it-compete-2017-11-20 | null | null | Galapagos ( GLPG ) stock popped Monday to Vertex Pharmaceuticals ' ( VRTX ) detriment after it figured out "one piece of its triple-combination puzzle" in treating cystic fibrosis, an analyst said.
[ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challengi... | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. Galapagos ( GLPG ) stock popped Monday to Vertex Pharmaceuticals ' ( VRTX ) detriment after it figured out "one piece of its triple-combination puzzle" in treating cystic fibro... | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. [ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Le... | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. Galapagos ( GLPG ) stock popped Monday to Vertex Pharmaceuticals ' ( VRTX ) detriment after it figured out "one piece of its triple-combination puzzle" in treating cystic fibro... | "There is a vast amount of work in front of Galapagos and its potential partner AbbVie ( ABBV ) to challenge Vertex in this category," he said. [ibd-display-video id=2839602 width=50 float=left autostart=true]Still, Galapagos still has a long road to truly challenging Vertex in treating cystic fibrosis, according to Le... |
25,845 | 2017-11-17 00:00:00 UTC | Notable ETF Inflow Detected - XLV, JNJ, PFE, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-jnj-pfe-abbv-2017-11-17 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.7 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 212,... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Cha... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price ... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Cha... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 1.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Cha... |
25,846 | 2017-11-17 00:00:00 UTC | Aristotle Capital Management, LLC Buys DowDuPont Inc, Capital One Financial Corp, Danaher Corp, ... | ABBV | https://www.nasdaq.com/articles/aristotle-capital-management-llc-buys-dowdupont-inc-capital-one-financial-corp-danaher | null | null | Aristotle Capital Management, LLC
New Purchases: DWDP , COF , EWBC , CCE, PEYUF, URPTF, SFRRF, KTWIF, KCDMF, GSK,
Added Positions:DHR, PPG, ACHC, NFG, GE, HD, BAX, MLM, PXD, HAL,
Reduced Positions:BBVA, MTB, FRC, UBS, SPY, BBVA, SCHW, BAM, UBS, IX,
Sold Out:TWX, NGG, DE,
For the details of Aristotle Capital Management,... | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Aristotle Capital Management, LLC New Purchases: DWDP , COF , EWBC , CCE, PEYUF, URPTF, SFRRF, KTWIF, KCDMF, GSK, Added Positions:DHR, PPG, ACHC, NFG, GE, HD, BAX, MLM, PXD, HAL, Reduced Positions:BBVA, MTB, FRC, UBS, SPY, BBVA,... | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. New Purchase: Coca-Cola European Partners PLC (CCE) Aristotle Capital Management, LLC initiated holdings in Coca-Cola European Partners PLC. New Purchase: Peyto Exploration & Development Corp (PEYUF) Aristotle Capital Management... | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Aristotle Capital Management, LLC New Purchases: DWDP , COF , EWBC , CCE, PEYUF, URPTF, SFRRF, KTWIF, KCDMF, GSK, Added Positions:DHR, PPG, ACHC, NFG, GE, HD, BAX, MLM, PXD, HAL, Reduced Positions:BBVA, MTB, FRC, UBS, SPY, BBVA,... | Shares added by 1.68% AbbVie Inc ( ABBV ) - 4,632,746 shares, 3.24% of the total portfolio. Added: AT&T Inc (T) Aristotle Capital Management, LLC added to the holdings in AT&T Inc by 26.56%. Aristotle Capital Management, LLC still held 585,045 shares as of 2017-09-30. |
25,847 | 2017-11-17 00:00:00 UTC | Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval | ABBV | https://www.nasdaq.com/articles/roches-rhhby-hemophilia-a-drug-receives-fda-approval-2017-11-17 | null | null | Roche HoldingsRHHBY announced that the FDA has approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
The approval comes three months ahead of the assigned PDUFA date of Feb 23, 2018. The ... | Roche's hematology portfolio consists of approved drugs like MabThera/Rituxan (rituximab), Gazyva/Gazyvara, and Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, Inc . ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Repor... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio consists of approve... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio consists of approve... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche's hematology portfolio consists of approve... |
25,848 | 2017-11-17 00:00:00 UTC | Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3 | ABBV | https://www.nasdaq.com/articles/biotechs-trading-lower-in-q4-on-macro-uncertainty-tepid-q3-2017-11-17 | null | null | The biotech industry turned around this year after the drug pricing issue crippled its performance last year.
It had a number of things going in its favor. Strong quarterly results, new product sales ramp up with rising demand, successful innovation and product line expansion, strong clinical study results, more freque... | Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Re... | Vertex VRTX and AbbVie ABBV were the only two outperformers in Q3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock... |
25,849 | 2017-11-15 00:00:00 UTC | 3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock | ABBV | https://www.nasdaq.com/articles/3-indisputable-reasons-why-abbvie-best-big-pharma-stock-2017-11-15 | null | null | What's the best big pharma stock?
Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others. And if one stock clearly dominates in several of those metrics, it has a strong argument in being named as the best.
AbbVi... | AbbVie's self-defined peer group of big pharma companies includes the ones already mentioned -- J&J, AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences -- plus Amgen , Eli Lilly , GlaxoSmithKline , Merck , Novartis , and Pfizer . A big pipeline disappointment and third-quarter revenue miss caused Celgene's stock pr... | Over the last three years (including estimated full-year earnings for 2017), AbbVie's adjusted earnings per share (EPS) have grown by 29%. Still, AbbVie clearly leads all other big pharma stocks in total return and adjusted EPS growth. AbbVie (NYSE: ABBV) is such a stock. | Total shareholder return Over the last three years, AbbVie's total shareholder return of more than 65% beats every other big pharma. A big pipeline disappointment and third-quarter revenue miss caused Celgene's stock price to sink , giving AbbVie the edge in total return this year. Still, AbbVie clearly leads all other... | AbbVie has increased its trailing-12-month revenue over the last three years by nearly 37%. AbbVie (NYSE: ABBV) is such a stock. Here are three indisputable reasons why AbbVie ranks as the best big pharma stock on the market right now. |
25,850 | 2017-11-15 00:00:00 UTC | 3 Stocks for Retirees to Grow Their Nest Eggs | ABBV | https://www.nasdaq.com/articles/3-stocks-retirees-grow-their-nest-eggs-2017-11-15 | null | null | Retired investors have somewhat different priorities than younger ones. Instead of focusing on growth, retirees' investments need to preserve their capital and also generate reliable income. However, that doesn't mean avoiding stocks -- in fact, there are some stocks that make excellent investments for retirees. Here's... | AbbVie CEO Richard Gonzalez recently stated that the company is interested in beefing up its portfolio through acquisitions and licensing deals, with a special focus in immunology and oncology. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even a... | A blue-chip biotech Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVie. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retiremen... | Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even after retirement. A blue-chip biotech Keith Speights (AbbVie) : Buying a biotech stock might not seem like a good idea for retirees, but I think there's one biotech that's a great choice -- AbbVi... | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. AbbVie is expected to increase earnings by 14% annually over the next few years. Here's why our contributors think Welltower (NYSE: HCN) , Nucor (NYSE: NUE) , and AbbVie (NYSE: ABBV) are worth a look, even ... |
25,851 | 2017-11-14 00:00:00 UTC | Novartis (NVS) Arm's Biosimilars Study Results Encourage | ABBV | https://www.nasdaq.com/articles/novartis-nvs-arms-biosimilars-study-results-encourage-2017-11-14 | null | null | Novartis AG'sNVS generic arm, Sandoz, reported data from four clinical studies. The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively.
The studies included two innovative trials involving switching and t... | The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV):... | The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV):... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The studies compared proposed biosimilar adalimumab ... | The studies compared proposed biosimilar adalimumab and biosimilar rituximab to reference drugs, AbbVie, Inc.'s ABBV Humira and Roche Holdings RHHBY MabThera respectively. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV):... |
25,852 | 2017-11-14 00:00:00 UTC | 3 Top Big Pharma Dividend Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-dividend-stocks-you-can-buy-right-now-2017-11-14 | null | null | Big pharma stocks have long been favorites for dividend-seeking investors, and for good reason. Major pharmaceutical companies typically generate strong cash flow, which allows them to pay high dividend yields for decades.
The great cash flow that enables big pharma companies to fund those attractive dividends stems fr... | AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. AbbVie The first thing investors like to know about a dividend stock is its yield. AbbVie doesn't disappoint in that category, with it... | AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. AbbVie The first thing investors like to know about a dividend stock is its yield. AbbVie doesn't disappoint in that category, with it... | There are big pharma stocks with higher yields than AbbVie (we'll soon discuss a couple of them), but few have the track record of dividend increases AbbVie does. With that kind of growth and higher dividends likely on the way as well, AbbVie looks like the best big pharma dividend stock of all. AbbVie (NYSE: ABBV) , N... | However, I think AbbVie is the best big pharma dividend stock overall. AbbVie (NYSE: ABBV) , Novartis (NYSE: NVS) , and Pfizer (NYSE: PFE) have balanced the reinvestment into new products with rewarding shareholders with solid dividends exceptionally well. AbbVie The first thing investors like to know about a dividend ... |
25,853 | 2017-11-13 00:00:00 UTC | Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study | ABBV | https://www.nasdaq.com/articles/arena-arna-completes-enrolment-in-etrasimod-phase-ii-study-2017-11-13 | null | null | Arena Pharmaceuticals, Inc. ARNA announced that it has completed full enrollment with 157 patients in a phase II study evaluating its pipeline candidate etrasimod in ulcerative colitis (UC). Etrasimod (APD334) is an orally available next-generation sphingosine 1-phosphate (S1P) receptor modulator.
The primary endpoint ... | Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorpor... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Another company,... | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Another company,... | Another company, AbbVie Inc. ABBV is also looking to get its flagship product Humira approved for UC. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Ligand Pharmaceuticals Incorpor... |
25,854 | 2017-11-13 00:00:00 UTC | Amgen Gets Positive CHMP Opinion to Expand Nplate's Label | ABBV | https://www.nasdaq.com/articles/amgen-gets-positive-chmp-opinion-to-expand-nplates-label-2017-11-13 | null | null | Amgen, Inc.AMGN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion to expand the label of Nplate to include the pediatric population.
Nplate is presently marketed for the treatment of chronic immune thrombocytopenic purpura (ITP) ... | Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from Ja... | (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this y... | However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from January 2023 Currently, Amgen has a Zacks Rank #3 (Hold). (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis R... | Its biosimilar version of Abbvie's ABBV rheumatoid arthritis drug Humira, Amjevita, was approved by the FDA last year and in the EU in March this year for the same indications. However, per a settlement with AbbVie, Amgen will begin selling Amjevita in most countries in the EU next year and in the United States from Ja... |
25,855 | 2017-11-12 00:00:00 UTC | 3 Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-id-buy-right-now-2017-11-12 | null | null | Thousands of stocks pay dividends. Some of those dividends aren't all that attractive, though. And sometimes the dividend looks great, but the stock doesn't. It could be there's a fundamental weakness for the business or simply that the stock's valuation is too pricey.
But there are a select group of stocks with terrif... | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. AbbVie I've been bullish about AbbVie for quite a while. And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. Even with its attractive dividend, solid business fundamentals, and tremendous growth prospects, AbbVie stock is still relatively inexpensive. AbbVie I've been bullish about AbbVie for quite a while. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. AbbVie I've been bullish about AbbVie for quite a while. And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%. | I think AbbVie (NYSE: ABBV) , Iron Mountain (NYSE: IRM) , and Medical Properties Trust (NYSE: MPW) definitely qualify. AbbVie I've been bullish about AbbVie for quite a while. And since being spun off from Abbott in 2013, AbbVie's dividend has increased a whopping 77%. |
25,856 | 2017-11-10 00:00:00 UTC | 7 Things AbbVie's Top Executives Just Said That You'll Want to Know | ABBV | https://www.nasdaq.com/articles/7-things-abbvies-top-executives-just-said-youll-want-know-2017-11-10 | null | null | It's a good time to be AbbVie (NYSE: ABBV) . And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong third-quarter performance a couple of weeks ago. AbbVie also increased its dividend for the 45th year in a row (including the years i... | Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. It's a good time to be AbbVie (NYSE: ABBV) . And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. | Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. Potential deals AbbVie's primary areas of focus for potential deals -- either acquisitions of companies or licensing assets -- are in immunology and oncology. It's a good t... | Beyond Humira While AbbVie believes Humira will remain a big moneymaker for years to come, it's looking beyond Humira to the next generation of autoimmune-disease drugs. Gonzalez said that potential disruptions by Amazon will "primarily impact the retail environment" and won't significantly affect AbbVie's business. Po... | AbbVie CFO Bill Chase pointed to two ways the company will be able to hit this projection. AbbVie's second priority, according to Gonzalez, is to return cash to shareholders through dividends and stock buybacks. It's a good time to be AbbVie (NYSE: ABBV) . |
25,857 | 2017-11-09 00:00:00 UTC | XLV, MRK, ABBV, AMGN: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-mrk-abbv-amgn-etf-outflow-alert-2017-11-09 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $106.2 million dollar outflow -- that's a 0.6% decrease week over week (from 213,315,324.0 to 212,015... | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.6%, AbbVie Inc (Symbol: ABBV) is up about 0.3%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price perf... |
25,858 | 2017-11-08 00:00:00 UTC | United Fire Group Inc Buys DowDuPont Inc, Nuveen Real Asset Income and Growth Fund, Brighthouse ... | ABBV | https://www.nasdaq.com/articles/united-fire-group-inc-buys-dowdupont-inc-nuveen-real-asset-income-and-growth-fund | null | null | United Fire Group Inc
New Purchases: DWDP , JRI , BHF ,
Reduced Positions:WFCPRL,
Sold Out:DRA, RBSPRHCL,
For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC
These are the top 5 holdings of UNITED FIRE GROUP INC
US Bancorp ( USB ) -... | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. United Fire Group Inc New Purchases: DWDP , JRI , BHF , Reduced Positions:WFCPRL, Sold Out:DRA, RBSPRHCL, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These ... | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. New Purchase: Nuveen Real Asset Income and Growth Fund (JRI) United Fire Group Inc initiated holdings in Nuveen Real Asset Income and Growth Fund. Sold Out: Diversified Real Asset Income Fund of Beneficial I (DRA) United Fire Group Inc sold out the hol... | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. United Fire Group Inc New Purchases: DWDP , JRI , BHF , Reduced Positions:WFCPRL, Sold Out:DRA, RBSPRHCL, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These ... | AbbVie Inc ( ABBV ) - 225,000 shares, 6.73% of the total portfolio. United Fire Group Inc New Purchases: DWDP , JRI , BHF , Reduced Positions:WFCPRL, Sold Out:DRA, RBSPRHCL, For the details of UNITED FIRE GROUP INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=UNITED+FIRE+GROUP+INC These ... |
25,859 | 2017-11-07 00:00:00 UTC | Welch Group, LLC Buys Microsoft Corp, DowDuPont Inc, SPDR Select Sector Fund - Energy Select ... | ABBV | https://www.nasdaq.com/articles/welch-group-llc-buys-microsoft-corp-dowdupont-inc-spdr-select-sector-fund-energy-select | null | null | Welch Group, LLC
New Purchases: DWDP , XLE , OKE , EUFN,
Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA,
Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE,
Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM,
For the details of Welch Group, LLC's stock buys and sells, go to http:... | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http:... | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http:... | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http:... | Welch Group, LLC New Purchases: DWDP , XLE , OKE , EUFN, Added Positions:MSFT, GIS, VZ, IBM, KMB, LEG, PAYX, CL, FB, NVDA, Reduced Positions:SFBS, MCD, JNJ, PFE, LMT, UL, ABBV, AJG, MMM, NEE, Sold Out:DD, DLPH, AMGN, RTN, FSP, SWKS, IP, OA, F, PHM, For the details of Welch Group, LLC's stock buys and sells, go to http:... |
25,860 | 2017-11-07 00:00:00 UTC | Stocks To Watch: Zoetis Sees RS Rating Rise To 82 | ABBV | https://www.nasdaq.com/articles/stocks-watch-zoetis-sees-rs-rating-rise-82-2017-11-07 | null | null | Zoetis ( ZTS ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 79 to 82.
[ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) score. The grade shows how a st... | AbbVie ( ABBV ) is the No. Zoetis ( ZTS ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 79 to 82. [ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) scor... | AbbVie ( ABBV ) is the No. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The views and opinions expressed herein are the views and opinions of the author and ... | AbbVie ( ABBV ) is the No. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ) is the No. Zoetis earns the No. 1-ranked stock within the group. |
25,861 | 2017-11-06 00:00:00 UTC | 5 Dividend Aristocrats With the Fastest-Growing Dividends | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-fastest-growing-dividends-2017-11-06 | null | null | Many investors like to buy stocks that are known as Dividend Aristocrats. To join this elite group, an S&P 500 company must increase its dividend for at least 25 consecutive years. But just how much those companies increase their dividends varies greatly. Some gain inclusion on the list of Dividend Aristocrats by makin... | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the com... | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the com... | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the com... | VF Corporation (NYSE: VFC) , AbbVie (NYSE: ABBV) , Medtronic (NYSE: MDT) , Illinois Tool Works (NYSE: ITW) , and Lowe's Companies (NYSE: LOW) have raised their dividends by more than 40% over the last three years. AbbVie Big biotech AbbVie's track record of annual dividend increases goes back 45 years, although the com... |
25,862 | 2017-11-04 00:00:00 UTC | These 3 Stocks Just Raised Their Dividends | ABBV | https://www.nasdaq.com/articles/these-3-stocks-just-raised-their-dividends-2017-11-04 | null | null | Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall earnings season. Still, the table was almost overflowing with goodies.
It was nearly impossible to choose only three appeti... | These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. | These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. | These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. | AbbVie Top pharmaceutical company AbbVie is hiking its quarterly payout yet again. These are VF Corporation (NYSE: VFC) , Aflac (NYSE: AFL) , and AbbVie (NYSE: ABBV) . AbbVie is a sprawling pharma producer, and it has many products on the shelves and in development. |
25,863 | 2017-11-03 00:00:00 UTC | Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug' | ABBV | https://www.nasdaq.com/articles/vertex-pops-analyst-questions-whether-rival-has-viable-drug-2017-11-03 | null | null | Vertex Pharmaceuticals ( VRTX ) and Galapagos ( GLPG ) stocks diverged Friday as one analyst suggested that while Galapagos has an interesting molecular formula, it may not have a viable cystic fibrosis drug on its hands.
[ibd-display-video id=2499417 width=50 float=left autostart=true]By the closing bell on the stock ... | AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials. AbbVie would likely prefer a more traditional and complete path to expensive Phase 3 testing, he said. | AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie has to fund and execute the Phase 3 trials. AbbVie would likely prefer a more traditional and complete path to expensive Phase 3 testing, he said. | "Such a decision doesn't seem imminent, which is fortunate for Galapagos, but will make for challenging times for Galapagos if AbbVie opts out, or doesn't advance any of the combinations." AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie ... | "Such a decision doesn't seem imminent, which is fortunate for Galapagos, but will make for challenging times for Galapagos if AbbVie opts out, or doesn't advance any of the combinations." AbbVie ( ABBV ) acquired the rights to Galapagos' cystic fibrosis combination program in 2013. Under the terms of the deal, AbbVie ... |
25,864 | 2017-11-02 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-union-pacific-bristol-myers-weyerhaeuser-and | null | null | For Immediate Release
Chicago, IL - November 2, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVieABBV , Union PacificU... | Stocks recently featured in the blog include AbbVieABBV , Union PacificUNP , Bristol-MyersBMY , WeyerhaeuserWY and ColgateCL . Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for AbbVie, Union Pacific and Bristol Myers The Zacks Research Daily presents the best research output of our analyst team. ... | Today's Research Daily features new research reports on 16 major stocks, including AbbVie, Union Pacific and Bristol-Myers. You can see all of today's research reports here >>> AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the ... | Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for AbbVie, Union Pacific and Bristol Myers The Zacks Research Daily presents the best research output of our analyst team. You can see all of today's research reports here >>> AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks ... | Here are highlights from Wednesday's Analyst Blog: Top Stock Reports for AbbVie, Union Pacific and Bristol Myers The Zacks Research Daily presents the best research output of our analyst team. You can see all of today's research reports here >>> AbbVie 's shares have gained +44.1% year to date, outperforming the Zacks ... |
25,865 | 2017-11-01 00:00:00 UTC | Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-amgen-gilead-hit-q3-results-vertex-beats-all-fronts-2017-11 | null | null | Major biotech companies reported earnings results over the last five trading days. While companies like Amgen AMGN and Vertex VRTX topped expectations, it was a mixed quarter for companies like Celgene CELG , Alexion (Read more: Alexion Tops Q3 Earnings, Lags Sales, 2017 View Up ) and BioMarin (Read more: BioMarin Q3 L... | AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corpor... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corpor... | AbbVie ABBV topped earnings estimates while revenues were in-line (Read more: AbbVie Q3 Earnings Top, Revenues In Line, View Up ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock... |
25,866 | 2017-11-01 00:00:00 UTC | If I Could Buy Only 1 Stock, This Would Be It | ABBV | https://www.nasdaq.com/articles/if-i-could-buy-only-1-stock-would-be-it-2017-11-01 | null | null | What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.
Second, I like dividends. The total return of a given stock includes both share-price appreciation and dividend reinvestment. When you have both, it's a wo... | Worries that AbbVie could face major competition in the U.S. have been largely alleviated after the company struck a deal recently with Amgen . Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. If I could buy only one stock right no... | Because of its connection with Abbott Labs, AbbVie boasts an impressive track record of increasing its dividend for 45 consecutive years. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. Growth We can only look back over the past five years to see how well AbbVie stock has performed. | Dividend There aren't many healthcare stocks with more attractive dividends than AbbVie. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. | If I could buy only one stock right now, AbbVie (NYSE: ABBV) would be it. Growth We can only look back over the past five years to see how well AbbVie stock has performed. But during those five years, AbbVie stock has nearly doubled the gains posted by the S&P 500 Index . |
25,867 | 2017-11-01 00:00:00 UTC | SFE Investment Counsel Buys ONEOK Inc, Amazon. ... | ABBV | https://www.nasdaq.com/articles/sfe-investment-counsel-buys-oneok-inc-amazon-2017-11-01 | null | null | SFE Investment Counsel
New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS,
Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI,
Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO,
Sold Out:BBBY, NWL, NAO,
For the details of SFE Investment Counsel's stock buys and sells, go to http:/... | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http:/... | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http:/... | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http:/... | SFE Investment Counsel New Purchases: AMZN , SQM , RYT , MCHP, DIN, BMY, GD, KS, Added Positions:OKE, FDX, KBE, GOOG, TXN, MKSI, GE, WAT, NUE, CMI, Reduced Positions:WSM, FLY, WFC, HP, ABT, AAPL, ABBV, WBA, MSB, THO, Sold Out:BBBY, NWL, NAO, For the details of SFE Investment Counsel's stock buys and sells, go to http:/... |
25,868 | 2017-11-01 00:00:00 UTC | Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come | ABBV | https://www.nasdaq.com/articles/seattle-genetics-inc-double-digit-revenue-growth-best-yet-come-2017-11-01 | null | null | Sales of Seattle Genetics 's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially considering that Adcetris has been on the market for six years. Fortunately, sales should accelerate from here with an expand... | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. What management had to say Darren Cline, Seattle Genetics' executive vice president of commercial, commented on doctors... | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. Also in December, investors will get a look at the ECHELON-1 data testing Adcetris in frontline advanced Hodgkin lympho... | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. Sales of Seattle Genetics 's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quar... | The rest of the revenue line comes from collaboration and licensing agreements, including a $12 million milestone from AbbVie (NYSE: ABBV) for the clinical trial progress with ABT 414 in glioblastoma. What happened with Seattle Genetics this quarter? And that's just for Adcetris. |
25,869 | 2017-10-31 00:00:00 UTC | HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View | ABBV | https://www.nasdaq.com/articles/hca-healthcare-hca-posts-in-line-q3-earnings-keeps-view-2017-10-31 | null | null | HCA Healthcare, Inc . HCA reported third-quarter 2017 adjusted earnings of $1.21 per share, which came in line with the Zacks Consensus Estimate. The bottom line declined nearly 25% year over year.
HCA Holdings, Inc. Price, Consensus and EPS Surprise
HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, ... | AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and... | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and... | AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis... |
25,870 | 2017-10-31 00:00:00 UTC | Artemis Investment Management LLP Buys Zions Bancorp, Equifax Inc, General Motors Co, Sells ... | ABBV | https://www.nasdaq.com/articles/artemis-investment-management-llp-buys-zions-bancorp-equifax-inc-general-motors-co-sells | null | null | Artemis Investment Management LLP
New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD,
Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE,
Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX, TTWO, TWO,
Sold Out:VZ, CTL, MET, SWFT, SAVE, TUP, TTMI, MS, MDC, LUV,
For the details of A... | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD, Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE, Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX... | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD, Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE, Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX... | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP New Purchases: MOS , BURL , XEC , CAT, LB, WBC, JNJ, INTU, BHI, MCD, Added Positions:ZION, EFX, GM, JPM, C, AA, AMAT, CVX, BAC, LITE, Reduced Positions:WDC, GLW, CMCSA, WFC, AAPL, SBUX, HD, TWX... | Shares added by 38.54% AbbVie Inc ( ABBV ) - 1,347,821 shares, 2.48% of the total portfolio. Artemis Investment Management LLP still held 1,351,667 shares as of 2017-09-30. Artemis Investment Management LLP still held 778,289 shares as of 2017-09-30. |
25,871 | 2017-10-31 00:00:00 UTC | iShares Russell 1000 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-inflow-2017-10-31 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 297,850,0... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel ... | Among the largest underlying components of IWF, in trading today Home Depot Inc (Symbol: HD) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Mastercard Inc (Symbol: MA) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel ... |
25,872 | 2017-10-30 00:00:00 UTC | Berkshire Asset Management Llc Buys Exxon Mobil Corp, Nucor Corp, Brighthouse Financial Inc, ... | ABBV | https://www.nasdaq.com/articles/berkshire-asset-management-llc-buys-exxon-mobil-corp-nucor-corp-brighthouse-financial-inc | null | null | Berkshire Asset Management Llc
New Purchases: BHF , RSP , APA , DWDP, PAYX, OKE, NVS, NVDA, CPRT, CLX,
Added Positions:XOM, NUE, T, GE, JPM, GIS, V, CB, PPL, QCOM,
Reduced Positions:ADP, SPY, VO, VB, HON, SCHF, AMGN, RDS.B, GOOGL, NSC,
Sold Out:GPC, KSS, VOT, BCR, VIA, TOL, TJX, RAI, EOG, EBAY,
For the details of BERKS... | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Berkshire Asset Management Llc New Purchases: BHF , RSP , APA , DWDP, PAYX, OKE, NVS, NVDA, CPRT, CLX, Added Positions:XOM, NUE, T, GE, JPM, GIS, V, CB, PPL, QCOM, Reduced Positions:ADP, SPY, VO, VB, HON, SCHF, AMGN, RDS.B, GOOGL,... | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Shares reduced by 0.49% New Purchase: Brighthouse Financial Inc (BHF) Berkshire Asset Management Llc initiated holdings in Brighthouse Financial Inc. New Purchase: Apache Corp (APA) Berkshire Asset Management Llc initiated holding... | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Berkshire Asset Management Llc New Purchases: BHF , RSP , APA , DWDP, PAYX, OKE, NVS, NVDA, CPRT, CLX, Added Positions:XOM, NUE, T, GE, JPM, GIS, V, CB, PPL, QCOM, Reduced Positions:ADP, SPY, VO, VB, HON, SCHF, AMGN, RDS.B, GOOGL,... | Shares added by 0.10% AbbVie Inc ( ABBV ) - 299,024 shares, 2.97% of the total portfolio. Berkshire Asset Management Llc still held 12,674 shares as of 2017-09-30. Berkshire Asset Management Llc still held 2,400 shares as of 2017-09-30. |
25,873 | 2017-10-30 00:00:00 UTC | Close Update: Wall Street's Winning Streak Snapped by Drug Sector, Tax Reform | ABBV | https://www.nasdaq.com/articles/close-update-wall-streets-winning-streak-snapped-drug-sector-tax-reform-2017-10-30 | null | null | The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well as by reports that lawmakers might consider altering the GOP tax reform plan, and after a member of President Donald Tru... | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well ... | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well ... | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well ... | Losses spilled into the rest of the pharmaceutical sector with Pfizer ( PFE ) and AbbVie ( ABBV ) down by more than 1%. The Dow Jones Industrial Average closed lower Monday, ending a three-day winning streak after investors cashed in on some of last week's gains ahead of a heavy economic and earnings calendar, as well ... |
25,874 | 2017-10-30 00:00:00 UTC | How Celgene, Gilead's Pricing Woes Continue To Haunt Biotech Stocks | ABBV | https://www.nasdaq.com/articles/how-celgene-gileads-pricing-woes-continue-haunt-biotech-stocks-2017-10-30 | null | null | Biotech stocks toppled last week following disappointing third-quarter results from the likes of Celgene ( CELG ) and Gilead Sciences ( GILD ), an analyst said Monday, noting that "competition and pricing concerns started taking a toll."
[ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of ne... | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Biotech stocks toppled last week following disappointing third-quarter results from the likes of Celgen... | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Gilead topped total sales views, but revenue from hepatitis C drugs declined by a third and narrowly mi... | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Biotech stocks toppled last week following disappointing third-quarter results from the likes of Celgen... | [ibd-display-video id=2461767 width=50 float=left autostart=true]The arrival of new competition in the form of AbbVie 's ( ABBV ) Mavyret forced Gilead's hepatitis C drug franchise to lose share in the third quarter. Gilead topped total sales views, but revenue from hepatitis C drugs declined by a third and narrowly mi... |
25,875 | 2017-10-29 00:00:00 UTC | In Your 60s? 3 Stocks You Should Consider Buying | ABBV | https://www.nasdaq.com/articles/your-60s-3-stocks-you-should-consider-buying-2017-10-29 | null | null | Some say that 60 is the new 40. Maybe so, but your attitude toward investing can be quite different in your 60s than they were in your 40s. With retirement either on the horizon or already a reality, you'll want to put your money in stocks of solid businesses that provide steady income.
Three stocks that definitely mee... | Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . AbbVie AbbVie provides the income that investors who are either retired or will be retired in the near future. AbbVie has also increased its dividend for 46 consecutive years... | Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . With strong current products and a deep pipeline, AbbVie should provide investors solid growth as well as a solid dividend. AbbVie AbbVie provides the income that investors w... | Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . AbbVie AbbVie provides the income that investors who are either retired or will be retired in the near future. AbbVie has also increased its dividend for 46 consecutive years... | That's huge, since two-thirds of AbbVie's revenue from the drug comes from the U.S. market. Three stocks that definitely meet those criteria are AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and IBM (NYSE: IBM) . AbbVie AbbVie provides the income that investors who are either retired or will be... |
25,876 | 2017-10-29 00:00:00 UTC | 5 Things You Need to Know From Gilead Sciences' Q3 Update | ABBV | https://www.nasdaq.com/articles/5-things-you-need-know-gilead-sciences-q3-update-2017-10-29 | null | null | You could probably fit the number of people surprised by Gilead Sciences ' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug sales plunged. HIV drug sales looked good. And Gilead still has a boatload of cash.
The more interesting aspect of Gilead's thi... | This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. | This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. | This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. | AbbVie's entrance into the market will hurt Gilead in two ways: It will take away market share and offer lower prices. This competition is coming from AbbVie 's (NYSE: ABBV) new HCV drug, Mavyret. Even if AbbVie wasn't a competitive threat, Gilead would still be facing a dismal outlook for its HCV products. |
25,877 | 2017-10-28 00:00:00 UTC | 3 High-Yield Dividend Aristocrat Stocks | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-aristocrat-stocks-2017-10-28 | null | null | If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the Dividend Aristocrats. It's comprised of S&P 500 stocks that have raised dividends for at least 25 years in a row.
Not all of t... | Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. | Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. | I have no doubt that AbbVie will remain a Dividend Aristocrat and a "growth aristocrat" for years to come, but that "value aristocrat" designation might not last much longer. Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): ... | Here's why they chose ExxonMobil (NYSE: XOM) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) . A three-in-one aristocrat Keith Speights (AbbVie): 1972. That's the year that started AbbVie's remarkable streak of dividend hikes. |
25,878 | 2017-10-27 00:00:00 UTC | AbbVie: The Dividend Does It? | ABBV | https://www.nasdaq.com/articles/abbvie-dividend-does-it-2017-10-27 | null | null | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie also reported better-than-expected earnings, and raised its 2017 earnings guidance.
T... | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. The market gave AbbVie's stock a boost on Sept. 28 when it was announced that the company ha... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from... | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie appears to have plenty of room to keep increasing its dividend, partly because its pa... | AbbVie's (ABBV) announcement this morning that it will increase its quarterly dividend by 11%, to 71 cents a share, is the latest in a series of hikes since the company was spun off from Abbott Laboratories (ABT) in early 2013. AbbVie appears to have plenty of room to keep increasing its dividend, partly because its pa... |
25,879 | 2017-10-27 00:00:00 UTC | Stocks With Rising Relative Strength: AstraZeneca | ABBV | https://www.nasdaq.com/articles/stocks-rising-relative-strength-astrazeneca-2017-10-27 | null | null | AstraZeneca ( AZN ) had its Relative Strength ( RS ) Rating upgraded from 69 to 79 Friday -- a welcome improvement, but still below the 80 or higher score you look for.
[ibd-display-video id=2102289 width=50 float=left autostart=true] IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) ... | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. AstraZeneca ( AZN ) had its Relative Strength ( RS ) Rating upgraded from 69 to 79 Friday -- a welcome improvement, but still below the 80 or higher score you look for. Over 100 years of market history r... | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Improved Price Performance? Why Should You Use IBD's Relative Strength Rating? | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Show... | AbbVie ( ABBV ), Grifols ( GRFS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group. See if AstraZeneca can continue to show renewed price strength and clear that threshold. Biotech And Pharmaceutical Industry And Stock News Which Stocks Are Showing Improved Price Performance? |
25,880 | 2017-10-27 00:00:00 UTC | Dow Stock Merck, AbbVie Top Earnings Views, Light On Sales | ABBV | https://www.nasdaq.com/articles/dow-stock-merck-abbvie-top-earnings-views-light-sales-2017-10-27 | null | null | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday.
[ibd-display-video id=2422711 width=50 float=left autostart=true]Merck felt the icy touch of investors as shares fell 4.4... | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. 'Just OK' AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges s... | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. 'Just OK' AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges s... | Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes when trading began early Friday. AbbVie, meanwhile, climbed 3.6% to hit 92.80. 'Just OK' AbbVie's quarter was "just OK," Leerink analyst Geoffrey Porges s... | And though Gilead struggled with its hepatitis C drug franchise, AbbVie's hepatitis C unit beat analysts' average by 24%, though sales declined by 26.8%. Dow component Merck ( MRK ) and AbbVie ( ABBV ) reported better-than-expected earnings, with sales light for both drugmakers, and the two met with diverging fortunes ... |
25,881 | 2017-10-27 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings Surpass Estimates, Guidance Raised | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-surpass-estimates-guidance-raised-2017-10-27 | null | null | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, acti... | AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is a... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's third-quarter earnings came ... |
25,882 | 2017-10-27 00:00:00 UTC | Q3 GDP Hits 3.0%, Q3 Earnings Take Pre-Market Higher | ABBV | https://www.nasdaq.com/articles/q3-gdp-hits-30-q3-earnings-take-pre-market-higher-2017-10-27 | null | null | Friday, October 27, 2017
Before we attempt to get our arms around another deluge of earnings reports ahead of the final opening bell of this trading week, we get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2's final read of 3.1%. This marks the firs... | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Fre... | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stoc... | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stoc... | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Fre... |
25,883 | 2017-10-27 00:00:00 UTC | Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat | ABBV | https://www.nasdaq.com/articles/gilead-gild-down-on-weak-hcv-sales-despite-q3-earnings-beat-2017-10-27 | null | null | Gilead Sciences, Inc.'sGILD reported third quarter 2017 results wherein both earnings and revenues surpassed expectations.
However, the stock is expected to open in the red given the decline in hepatitis C virus (HCV) franchise. Nevertheless, Gilead's stock has gained 15.2% year to date as against the industry's declin... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Repo... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Repo... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni,... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie, Inc.'s ABBV Viekira Pak and Viekira XR and Bristol-Myers Squibb Company's BMY Daklinza among others. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Repo... |
25,884 | 2017-10-27 00:00:00 UTC | Data and Earnings Deluge | ABBV | https://www.nasdaq.com/articles/data-and-earnings-deluge-2017-10-27 | null | null | Before we attempt to get our arms around another deluge of earnings reports ahead of the final opening bell of this trading week, we get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2's final read of 3.1%. This marks the first time since 2014 the U.S... | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Fre... | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stoc... | Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Phillips 66 (PSX): Free Stoc... | Also, biopharma firm AbbVie ABBV , which had branched off from Abbott Labs in 2013, beat earnings estimates by 2 cents to $1.41 per share, whereas revenues of $7 billion came in basically in-line with estimates. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Fre... |
25,885 | 2017-10-27 00:00:00 UTC | AbbVie Inc (ABBV) Earnings: 12 Things to Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-earnings-12-things-know-2017-10-27 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017.
Source: Shutterstock
Here are a few things to know about AbbVie Inc's recent earnings report.
The company reported earnings per share of $1.41 on revenue of $7.00 billi... | Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Wall Street is expecting ABBV to report earnings per share of $5.53 for the year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report f... | Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Wall Street is expecting ABBV to report earnings per share of $5.53 for the year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report f... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017. Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Source: Shutterstock Here are a few things to know a... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) has released its earnings report for the third quarter of 2017. The post AbbVie Inc (ABBV) Earnings: 12 Things to Know appeared first on InvestorPlace . Source: Shutterstock Here are a few things to know about AbbVie Inc's recent ea... |
25,886 | 2017-10-26 00:00:00 UTC | Westchester Capital Management, Inc. Buys Exxon Mobil Corp, Alphabet Inc, JPMorgan Chase, Sells ... | ABBV | https://www.nasdaq.com/articles/westchester-capital-management-inc-buys-exxon-mobil-corp-alphabet-inc-jpmorgan-chase-sells | null | null | Westchester Capital Management, Inc.
New Purchases: GOOGL , JPM ,
Added Positions: XOM , PFE, BDX, VLO, MCHP, AGN, LMT, DIS, CVS, CSCO,
Reduced Positions:GLD, SDY, CVX, F,
For the details of Westchester Capital Management, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Westchester+Cap... | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Westchester Capital Management, Inc. New Purchases: GOOGL , JPM , Added Positions: XOM , PFE, BDX, VLO, MCHP, AGN, LMT, DIS, CVS, CSCO, Reduced Positions:GLD, SDY, CVX, F, For the det... | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Shares added by 0.78% New Purchase: Alphabet Inc ( GOOGL ) Westchester Capital Management, Inc. initiated holdings in Alphabet Inc. New Purchase: JPMorgan Chase & Co (JPM) Westchester... | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. Westchester Capital Management, Inc. New Purchases: GOOGL , JPM , Added Positions: XOM , PFE, BDX, VLO, MCHP, AGN, LMT, DIS, CVS, CSCO, Reduced Positions:GLD, SDY, CVX, F, For the det... | These are the top 5 holdings of Westchester Capital Management, Inc. AbbVie Inc ( ABBV ) - 147,498 shares, 5.62% of the total portfolio. The holdings were 8 shares as of 2017-09-30. GuruFocus has detected 5 Warning Signs with XOM. |
25,887 | 2017-10-26 00:00:00 UTC | Gilead Sciences, Inc. Stock Looks Good Regardless of Quarterly Earnings Report | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc.-stock-looks-good-regardless-of-quarterly-earnings-report-2017-10-26 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
However Gilead Sciences, Inc. (NASDAQ: GILD ) quarterly earnings report ends up after the market close (October 26), the stock's valuation still looks very compelling. Ideally, investors would want the company reporting stronger Hepatitis C drug sales, and ... | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch h... | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch h... | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch h... | Competition for HCV Drug Last August, the FDA approved AbbVie Inc's (NYSE: ABBV ) Mavyret (glecaprevir and pibrentasvir), which treats adult patients with genotypes 1 - 6 chronic hepatitis C virus. Ahead of the approval, Gilead's management said it would review AbbVie's label on the drug, check the pricing, and watch h... |
25,888 | 2017-10-26 00:00:00 UTC | Key Predictions for Q3 Earnings Reports of ABBV, MRK | ABBV | https://www.nasdaq.com/articles/key-predictions-for-q3-earnings-reports-of-abbv-mrk-2017-10-26 | null | null | The third-quarter reporting cycle is witnessing revenue acceleration and a positive revisions trend for Q4.
Results from about one-third (164 companies) of the S&P 500 members are already out. The revenue beat ratio for these companies is 68.3%, slightly below the preceding quarter (68.9%), which itself was unusually h... | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. For this quarter, Abbvie has an Earnings ESP of almost 0.00% and a Zacks Rank #3 (Hold). This quarter, AbbVie expects Humira sales to rise in the high-teens range whi... | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Merck & Co., Inc.MRK Merck which is scheduled to release earnings before the market opens. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Abb... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com clic... | AbbVie Inc.ABBV AbbVie, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 1.43% last quarter. For this quarter, Abbvie has an Earnings ESP of almost 0.00% and a Zacks Rank #3 (Hold). This quarter, AbbVie expects Humira sales to rise in the high-teens range whi... |
25,889 | 2017-10-26 00:00:00 UTC | Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-beats-on-q3-earnings-sales-raises-2017-view-2017-10-26 | null | null | Vertex Pharmaceuticals IncorporatedVRTX reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter.
Vertex reported revenues of $578.2 million in the thi... | Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Repo... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian compan... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report To read this article on Zacks.com click here. Belgian compan... | Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to Vertex's triple combo regimens. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Repo... |
25,890 | 2017-10-26 00:00:00 UTC | 5 Things You'll Want to Watch With AbbVie's Q3 Results | ABBV | https://www.nasdaq.com/articles/5-things-youll-want-watch-abbvies-q3-results-2017-10-26 | null | null | If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-alone company in 2013. AbbVie has enjoyed good news for its current products and its pipeline.
But the year isn't over yet. Abb... | Bill Chase, Abbvie's CFO, stated in July that a falling U.S. dollar could cause gross margin to be lower due to these hedges. If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-a... | Imbruvica's growth -- especially in first-line CLL While Humira remains AbbVie's top-selling product, Imbruvica is its fastest-growing drug. How big of a dividend hike Technically, AbbVie's dividend increase announcements are made separately from quarterly results. If 2017 ended right now, it would go down as AbbVie 's... | Imbruvica's growth -- especially in first-line CLL While Humira remains AbbVie's top-selling product, Imbruvica is its fastest-growing drug. AbbVie made $626 million in the second quarter from Imbruvica (including international profits shared with partner Johnson & Johnson), a 43% year-over-year jump. How big of a divi... | A weaker dollar is usually good news for international sales, which represent one-third of AbbVie's total revenue. If 2017 ended right now, it would go down as AbbVie 's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-alone compan... |
25,891 | 2017-10-26 00:00:00 UTC | Notable Thursday Option Activity: PX, ABBV, DMRC | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-px-abbv-dmrc-2017-10-26 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Praxair Inc (Symbol: PX), where a total volume of 4,010 contracts has been traded thus far today, a contract volume which is representative of approximately 401,000 underlying shares (given that every 1... | Especially high volume was seen for the $88 strike put option expiring October 27, 2017 , with 2,391 contracts trading so far today, representing approximately 239,100 underlying shares of ABBV. Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (... | Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past mo... | Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past mo... | Below is a chart showing PX's trailing twelve month trading history, with the $150 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,253 contracts, representing approximately 2.5 million underlying shares or approximately 43% of ABBV's average daily trading volume over the past mo... |
25,892 | 2017-10-26 00:00:00 UTC | Gilead Tops Sales, Profit Views But Misses On Hep C; Shares Fall | ABBV | https://www.nasdaq.com/articles/gilead-tops-sales-profit-views-misses-hep-c-shares-fall-2017-10-26 | null | null | Gilead Sciences ( GILD ) topped sales and adjusted profits views in the third quarter, but shares dropped late Thursday after its hepatitis C drug franchise declined again and narrowly missed consensus expectations.
[ibd-display-video id=2422292 width=50 float=left autostart=true]In after-hours trading on the stock mar... | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Gilead Sciences ( GILD ) topped sales and adjusted profits views in the... | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Flagship HIV drug Genvoya posted a yearly gain of 114% to $988 million ... | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Gilead Sciences ( GILD ) topped sales and adjusted profits views in the... | This follows the entry of AbbVie 's ( ABBV ) Mavyret which can treat all six genotypes of hepatitis C. RBC's Abrahams noted hepatitis C drug Harvoni came in "considerably lighter than expectations" at $973 million vs. the consensus at $1.1 billion. Gilead Sciences ( GILD ) topped sales and adjusted profits views in the... |
25,893 | 2017-10-26 00:00:00 UTC | Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-misses-on-q3-earnings-opdivo-in-focus-2017-10-26 | null | null | Bristol-Myers Squibb Company 's BMY third-quarter 2017 earnings of 75 cents per share fell short of the Zacks Consensus Estimate as well as the year-ago quarter earnings of 77 cents.
However, total revenue of $5.25 billion came ahead of the Zacks Consensus Estimate of $5.2 billion as well as $4.9 billion recorded in th... | These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, In... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. These include Daiichi Sanky... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. These include Daiichi Sanky... | These include Daiichi Sankyo's investigational candidate DS-8201, AbbVie Inc's ABBV ABBV-399, Exelixis, Inc.'s EXEL Cabometyx and Clovis Oncology, Inc.'s CLVS Rubraca. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exelixis, In... |
25,894 | 2017-10-26 00:00:00 UTC | Must-Watch Earnings Charts to End the Week | ABBV | https://www.nasdaq.com/articles/must-watch-earnings-charts-end-week-2017-10-26 | null | null | This is a big week for earnings, with over 800 companies expected to report, including many Dow Industrial and S&P 500 companies.
In addition to some of the top technology titans, there are also a handful of other companies that you should keep an eye on.
These companies are on everyone's list because they are breaking... | AbbVie ABBV has missed only once since its 2013 spin-off from Abbott Labs. Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Spor... | Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Z... | Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Z... | Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Baidu, Inc. (BIDU): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report To read this article on Z... |
25,895 | 2017-10-25 00:00:00 UTC | Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q3-earnings-gileads-car-t-drug-gets-fda-nod-2017-10-25 | null | null | Biogen's BIIB third quarter results surpassed both top-and bottom-line expectations. Meanwhile, Gilead's GILD CAR T therapy gained earlier-than-expected FDA approval. Alexion ALXN also got a regulatory boost with the FDA expanding the label of the company's flagship product, Soliris.
Recap of the Week's Most Important ... | AbbVie Announces Immuno-Therapy Focused Deals: AbbVie ABBV announced a couple of deals this week. The immuno-neurology deal will see AbbVie collaborating with Alector for the use of the latter's immuno-neurology discovery platform for innovative new therapies for Alzheimer's disease and other neurological disorders. Me... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Re... |
25,896 | 2017-10-25 00:00:00 UTC | 10 Healthcare Stocks to Buy for a Dividend Lifeline | ABBV | https://www.nasdaq.com/articles/10-healthcare-stocks-to-buy-for-a-dividend-lifeline-2017-10-25 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks are no strangers to uncertainty. There's continued talk about changes to U.S. healthcare laws, and disruption to the statewide insurance exchanges that were created as part of the Affordable Care Act.
Source: Shutterstock
But for long-term... | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previou... | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previou... | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previou... | Healthcare Stocks to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Market Cap: $145 billion Dividend Yield: 2.8% 2017 Return: 47% vs. 15% for the S&P 500 AbbVie Inc (NYSE: ABBV ) was spun off of Big Pharma mainstay Abbot Laboratories (NYSE: ABT ) in 2013, and it is the drug-focused arm of the previou... |
25,897 | 2017-10-25 00:00:00 UTC | Gierl Augustine Investment Management Inc Buys iShares International Select Dividend, Vanguard ... | ABBV | https://www.nasdaq.com/articles/gierl-augustine-investment-management-inc-buys-ishares-international-select-dividend | null | null | Gierl Augustine Investment Management Inc
New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO,
Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM,
Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG,
Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP,
For the detai... | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the detai... | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the detai... | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the detai... | Gierl Augustine Investment Management Inc New Purchases: IDV , VOT , VNQ , VTI, MDYG, SCHH, DWDP, CWB, SHW, VOO, Added Positions:MSA, AAPL, FE, MCD, T, BP, GE, INTC, VZ, XOM, Reduced Positions:JNK, VEA, VUG, VWO, IJR, EEM, EMB, SHY, IJH, SCHG, Sold Out:IWB, EFA, DD, VGK, IWM, DGAS, AQMS, SLB, GOOGL, SHOP, For the detai... |
25,898 | 2017-10-24 00:00:00 UTC | Can AbbVie (ABBV) Spring a Surprise this Earnings Season? | ABBV | https://www.nasdaq.com/articles/can-abbvie-abbv-spring-a-surprise-this-earnings-season-2017-10-24 | null | null | AbbVie Inc.ABBV is scheduled to release third-quarter 2017 earnings on Oct 27, before the opening bell.
AbbVie's shares have soared 47.8% so far this year, while the industry has recorded an increase of 20.2%.
Last quarter, the company delivered a positive surprise of 1.43%. Notably, AbbVie's earnings history is a mixe... | Notably, AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily HCV treatment, Mavyret/Maviret, gained approval in the United States, EU and Canada earlier in July/August. AbbVie and partner Roche RHHBY announced positive data from a phase III MURANO study of Venclexta plus Rituxan in September to expand the la... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks Rank: Though AbbVie's Zacks Rank #3 increases the predictive power of ESP, its 0.00% Earnings ESP makes the surprise prediction difficult. Click to get this f... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Let's see how things are shaping up for the company this quarter. Zacks ESP: AbbVie has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.39 per share. Click to get this ... | Zacks ESP: AbbVie has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.39 per share. AbbVie Inc.ABBV is scheduled to release third-quarter 2017 earnings on Oct 27, before the opening bell. AbbVie's shares have soared 47.8% so far this year, while the industry... |
25,899 | 2017-10-24 00:00:00 UTC | 3 Healthcare Value Stocks | ABBV | https://www.nasdaq.com/articles/3-healthcare-value-stocks-2017-10-24 | null | null | The words "healthcare" and "value" don't seem to go together in the stock market right now as the sector has been hot in 2017, but that's only if you look at traditional valuation metrics and not the long-term potential.
While you can still find a few stocks that offer up an attractive price right now, foresighted inve... | While much focus is rightly placed on AbbVie's Humira, from which the company derives about two-thirds of its $25.6 billion in annual revenue, it's the pipeline of therapies the drugmaker has in its portfolio that really argues in favor of its stock being discounted now. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ:... | Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of good value and good potential. A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer ... | A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of goo... | A pipeline to future growth Rich Duprey(AbbVie): A stock that's regularly hitting new 52-week highs might not look like your typical value stock, but drug manufacturer AbbVie still fits the bill. Gilead Sciences (NASDAQ: GILD) , Masimo (NASDAQ: MASI) , and AbbVie (NYSE: ABBV) provide investors with a combination of goo... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.